Kura Historical Income Statement
KURA Stock | USD 17.68 0.09 0.51% |
Historical analysis of Kura Oncology income statement accounts such as Selling General Administrative of 53.1 M can show how well Kura Oncology performed in making a profits. Evaluating Kura Oncology income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Kura Oncology's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Kura Oncology latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Kura Oncology is a good buy for the upcoming year.
Kura |
About Kura Income Statement Analysis
Kura Oncology Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Kura Oncology shareholders. The income statement also shows Kura investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Kura Oncology Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Kura Oncology. It is also known as Kura Oncology overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Cost Of Revenue
Cost of Revenue is found on Kura Oncology income statement and represents the costs associated with goods and services Kura Oncology provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Depreciation And Amortization
The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.Most accounts from Kura Oncology's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Kura Oncology current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kura Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.At present, Kura Oncology's Other Operating Expenses is projected to increase significantly based on the last few years of reporting. The current year's Total Operating Expenses is expected to grow to about 174.1 M, whereas Operating Income is projected to grow to (157.5 M).
Kura Oncology income statement Correlations
Click cells to compare fundamentals
Kura Oncology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Kura Oncology income statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Other Operating Expenses | 67.5M | 91.9M | 131.3M | 139.9M | 165.8M | 174.1M | |
Operating Income | (67.5M) | (92.1M) | (131.8M) | (140.6M) | (165.8M) | (157.5M) | |
Ebit | (67.5M) | (92.1M) | (131.8M) | (140.6M) | (165.8M) | (157.5M) | |
Ebitda | (67.5M) | (91.9M) | (131.3M) | (139.9M) | (165.0M) | (156.7M) | |
Total Operating Expenses | 67.5M | 91.9M | 131.3M | 139.9M | 165.8M | 174.1M | |
Income Before Tax | (63.1M) | (89.6M) | (130.5M) | (135.8M) | (152.6M) | (145.0M) | |
Net Income | (63.1M) | (89.4M) | (129.9M) | (136.1M) | (152.6M) | (145.0M) | |
Interest Expense | 580K | 578K | 414K | 229K | 1.5M | 1.6M | |
Selling General Administrative | 19.7M | 31.5M | 46.5M | 47.1M | 50.6M | 53.1M | |
Total Other Income Expense Net | 4.3M | 2.5M | 1.4M | 4.8M | 13.2M | 13.8M | |
Net Income From Continuing Ops | (63.1M) | (89.6M) | (130.5M) | (135.8M) | (143.0M) | (135.8M) | |
Net Income Applicable To Common Shares | (63.1M) | (89.6M) | (130.5M) | (135.8M) | (122.3M) | (116.1M) | |
Depreciation And Amortization | 10.0 | 194K | 558K | 759K | 849K | 891.5K | |
Research Development | 47.8M | 60.4M | 84.7M | 92.8M | 115.2M | 121.0M | |
Income Tax Expense | (4.9M) | (194K) | (558K) | 229K | 206.1K | 216.4K | |
Interest Income | 4.7M | 2.8M | 1.2M | 4.3M | 12.6M | 13.3M | |
Non Operating Income Net Other | 4.9M | 2.9M | 1.2M | 4.3M | 4.9M | 2.8M | |
Net Interest Income | 4.1M | 2.2M | 792K | 4.0M | 11.2M | 11.8M | |
Reconciled Depreciation | 12K | 194K | 558K | 759K | 841K | 883.1K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Kura Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kura Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kura Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kura Oncology Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kura Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. If investors know Kura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kura Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.35) | Return On Assets (0.29) | Return On Equity (0.46) |
The market value of Kura Oncology is measured differently than its book value, which is the value of Kura that is recorded on the company's balance sheet. Investors also form their own opinion of Kura Oncology's value that differs from its market value or its book value, called intrinsic value, which is Kura Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kura Oncology's market value can be influenced by many factors that don't directly affect Kura Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kura Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kura Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kura Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.